SCHEMBL167606

SCHEMBL167606

Fc1ccc(OCCCCl)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 3/20 0.56
DRD3 P35462 3/20 0.56
DRD4 P21917 2/20 0.56
MEN1 O00255 1/20 0.50
LMNA P02545 1/20 0.50
HTT P42858 1/20 0.50
KMT2A Q03164 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C19 P33261 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
USP2 O75604 1/20 0.49
ALDH1A1 P00352 1/20 0.49
HPGD P15428 1/20 0.49
HRH3 Q9Y5N1 1/20 0.49
KDM4E B2RXH2 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
TSHR P16473 1/20 0.46
LTA4H P09960 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5252735 0.93 DRD2 (0.55) DRD2DRD3DRD4MEN1LMNA
SCHEMBL5248320 0.91 DRD2 (0.52) DRD2DRD3DRD4MEN1LMNA
SCHEMBL10338308 0.87 MEN1 (0.60) DRD2DRD3DRD4MEN1LMNA
SCHEMBL11093336 0.87 KCNA3 (0.52) DRD2DRD3DRD4CYP2D6L3MBTL1
SCHEMBL9114592 0.85 CYP1A2 (0.63) DRD2DRD3DRD4MEN1LMNA
SCHEMBL9047325 0.83 TSHR (0.53) DRD2DRD3DRD4MEN1KMT2A
SCHEMBL28924895 0.83 DRD2 (0.42) DRD2DRD3DRD4MEN1LMNA
SCHEMBL28387678 0.82 DRD2 (0.43) DRD2DRD3DRD4MEN1LMNA
SCHEMBL4270834 0.81 TSHR (0.64) DRD2DRD3DRD4CYP1A2CYP2D6
SCHEMBL11096825 0.80 CYP3A4 (0.52) CYP1A2CYP2D6CYP2C19HRH3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3898581-B1 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS INTRA CELLULAR THERAPIES INC (US) 2025-08-27 EP claimed
US-12297200-B2 Substituted heterocycle fused gamma-carbolines synthesis INTRA-CELLULAR THERAPIES, INC. (US) 2025-05-13 US claimed
CN-116332580-B Preparation method for preparing simulated stone by using chrome-containing leather ash 烟台大学 2025-02-18 CN claimed
US-20240279228-A1 NOVEL SALTS AND CRYSTALS INTRA-CELLULAR THERAPIES, INC. 2024-08-22 US claimed
CN-113195450-B Synthesis of substituted heterocycle fused gamma-carbolines 细胞内治疗公司 2024-04-26 CN claimed
EP-4352057-A1 NOVEL SALTS AND CRYSTALS Intra-Cellular Therapies, Inc. (US) 2024-04-17 EP claimed
CN-117425652-A Novel salts and crystals 细胞内治疗公司 2024-01-19 CN claimed
CN-116332580-A Preparation method for preparing simulated stone by using chrome-containing leather ash 烟台大学 2023-06-27 CN claimed
WO-2022261633-A1 NOVEL SALTS AND CRYSTALS INTRA-CELLULAR THERAPIES, INC. (US) 2022-12-15 WO claimed
EP-2134710-B1 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS INTRA CELLULAR THERAPIES INC (US) 2020-02-12 EP claimed
US-9751883-B2 Preparation of certain [((6BR,10AS)-2,3,6B,7,8,9,10, 10A-octahydro-1H-pyrido[3′,4′:4,5]pyrrolo [1,2,3-de]quinoxalines and pharmaceutically acceptable salts thereof INTRA-CELLULAR THERAPIES, INC. (US) 2017-09-05 US claimed
US-20140364609-A1 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS INTRA-CELLULAR THERAPIES, INC. 2014-12-11 US claimed
CN-103626766-A Substituted heterocycle fused gamma-carbolines synthesis INTRA CELLULAR THERAPIES INC 2014-03-12 CN claimed
CN-101796051-B Synthesis of substituted heterocycle fused gamma-carbolines INTRA CELLULAR THERAPIES INC 2013-11-06 CN claimed
EP-0076530-B1 NOVEL N-(3-HYDROXY-4-PIPERIDINYL)BENZAMIDE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1985-12-11 EP claimed
EP-0076530-A2 Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives JANSSEN PHARMACEUTICA N.V. (BE) 1983-04-13 EP claimed
US-20260098040-A1 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS INTRA CELLULAR THERAPIES INC (US) 2026-04-09 US disclosed
EP-3609891-B1 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS INTRA CELLULAR THERAPIES INC (US) 2026-02-11 EP disclosed
US-4010280-A PHENOXYALKYLAMINE DERIVATIVES AND PREPARATION THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JA) 1977-03-01 US disclosed
US-3965106-A 3-Phenoxypropylamine derivatives SUMITOMO CHEMICAL COMPANY, LIMITED (JA) 1976-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240279228-A1 NOVEL SALTS AND CRYSTALS SLC6A12, UACA, CYCS DRD2 468/4885DRD3 463/4885DRD4 255/4885
US-20140364609-A1 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS HCCS, CYCS, CBR3 DRD2 209/4885DRD3 350/4885DRD4 166/4885
US-20260098040-A1 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS KCNH2, KCNH3, KCNH1 DRD2 660/4885DRD3 941/4885DRD4 1161/4885
US-12297200-B2 Substituted heterocycle fused gamma-carbolines synthesis HCCS, CYCS, CBR3 DRD2 221/4885DRD3 372/4885DRD4 176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.